English

Factory Supply Rosuvastatin Calcium 20 Mg Tablet - Dabigatran Etexilate Mesylate – CPF

Factory Supply Rosuvastatin Calcium 20 Mg Tablet - Dabigatran Etexilate Mesylate – CPF Featured Image
  • Factory Supply Rosuvastatin Calcium 20 Mg Tablet - Dabigatran Etexilate Mesylate – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

The consumer fulfillment is our primary goal. We uphold a consistent level of professionalism, top quality, credibility and service for Doxycycline Monohydrate Yeast Infection, Tofacitinib Citrate, Doxycycline Monohydrate For Chlamydia, Our products are regularly supplied to many Groups and lots of Factories. Meanwhile, our products are sold to the USA, Italy, Singapore, Malaysia, Russia, Poland, and the Middle East.
Factory Supply Rosuvastatin Calcium 20 Mg Tablet - Dabigatran Etexilate Mesylate – CPF Detail:

Description

Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.

Background

Description: IC50 Value: 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1] Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate. in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2]. Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1

Storage

Powder

-20°C

 3 years
 

4°C

 2 years
In solvent

-80°C

 6 months
 

-20°C

 1 month

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase
NCT02170792 Boehringer Ingelheim Healthy February 2001

Phase 1
NCT02170974 Boehringer Ingelheim Healthy July 2004

Phase 1
NCT02170831 Boehringer Ingelheim Healthy May 1999

Phase 1
NCT02170805 Boehringer Ingelheim Healthy April 2001

Phase 1
NCT02170610 Boehringer Ingelheim Healthy March 2002

Phase 1
NCT02170909 Boehringer Ingelheim Healthy December 2004

Phase 1
NCT02171000 Boehringer Ingelheim Healthy April 2005

Phase 1
NCT02170844 Boehringer Ingelheim Healthy June 2004

Phase 1
NCT02170584 Boehringer Ingelheim Healthy January 2001

Phase 1
NCT02170935 Boehringer Ingelheim Venous Thromboembolism April 2002

Phase 2
NCT02170636 Boehringer Ingelheim Healthy January 2002

Phase 1
NCT02170766 Boehringer Ingelheim Healthy October 2000

Phase 1
NCT02171442 Boehringer Ingelheim Healthy April 2002

Phase 1
NCT02170896 Boehringer Ingelheim Healthy October 2001

Phase 1
NCT02173730 Boehringer Ingelheim Healthy November 2002

Phase 1
NCT02170623 Boehringer Ingelheim Healthy February 2002

Phase 1
NCT02170116 Boehringer Ingelheim Healthy November 1998

Phase 1
NCT02170597 Boehringer Ingelheim Healthy August 2003

Phase 1
NCT01225822 Boehringer Ingelheim Venous Thromboembolism November 2002

Phase 2
NCT02170701 Boehringer Ingelheim Venous Thromboembolism October 2000

Phase 2
NCT02170740 Boehringer Ingelheim Healthy November 1999

Phase 1
NCT02170922 Boehringer Ingelheim Healthy July 1999

Phase 1

Chemical structure

Dabigatran Etexilate Mesylate

2018 GMP-2
原料药GMP证书201811（captopril ,thalidomide etc）
GMP-of-PMDA-in-Chanyoo-平成28年08月03日　Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation

Product detail pictures:

Factory Supply Rosuvastatin Calcium 20 Mg Tablet - Dabigatran Etexilate Mesylate – CPF detail pictures

Related Product Guide:
Our enterprise insists all along the standard policy of "product high-quality is base of business survival; client satisfaction could be the staring point and ending of an business; persistent improvement is eternal pursuit of staff" as well as consistent purpose of "reputation first, client first" for Factory Supply Rosuvastatin Calcium 20 Mg Tablet - Dabigatran Etexilate Mesylate – CPF , The product will supply to all over the world, such as: Estonia, Rio de Janeiro, Indonesia, We have been seeking the chances to meet all the friends from both at home and abroad for the win-win cooperation. We sincerely hope to have long-term cooperation with all of you on the bases of mutual benefit and common development.
    • This manufacturer can keep improving and perfecting products and service, it is in line with the rules of market competition, a competitive company.
    5 Stars By Mavis from Canberra - 2017.09.16 13:44
    With a positive attitude of "regard the market, regard the custom, regard the science", the company works actively to do research and development. Hope we have a future business relationships and achieving mutual success.
    5 Stars By Marco from United Arab Emirates - 2017.12.31 14:53
    Write your message here and send it to us

    Products categories